CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...